f IL-17 Antagonists as a Promising Therapeutic Modality for Hidradenitis Suppurativa

References

1. SabatR. JemecG.B.E. MatusiakŁ. KimballA.B. PrensE. WolkK. Hidradenitis suppurativa.Nat. Rev. Dis. Primers2020611810.1038/s41572‑020‑0149‑1 32165620
   [Google Scholar]
2. KrajewskiP.K. MatusiakŁ. von StebutE. Quality-of-life impairment among patients with hidradenitis suppurativa: A cross-sectional study of 1795 patients.Life20211113410.3390/life11010034 33429896
   [Google Scholar]
3. MatusiakŁ. Profound consequences of hidradenitis suppurativa: A review.Br. J. Dermatol.20201836e171e17710.1111/bjd.16603 29744872
   [Google Scholar]
4. ZouboulisC.C. DesaiN. EmtestamL. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.J. Eur. Acad. Dermatol. Venereol.201529461964410.1111/jdv.12966 25640693
   [Google Scholar]
5. SchlapbachC. HänniT. YawalkarN. HungerR.E. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa.J. Am. Acad. Dermatol.201165479079810.1016/j.jaad.2010.07.010 21641076
   [Google Scholar]
6. WolkK. WarszawskaK. HoeflichC. Deficiency of IL-22 contributes to a chronic inflammatory disease: Pathogenetic mechanisms in acne inversa.J. Immunol.201118621228123910.4049/jimmunol.0903907 21148041
   [Google Scholar]
7. SabatR. GudjonssonJ.E. BrembillaN.C. van StraalenK.R. WolkK. Biology of interleukin-17 and novel therapies for hidradenitis suppurativa.J. Interferon Cytokine Res.2023431254455610.1089/jir.2023.0105 37824200
   [Google Scholar]
8. MatusiakŁ. SzczęchJ. BieniekA. Nowicka-SuszkoD. SzepietowskiJ.C. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents.J. Am. Acad. Dermatol.201776467067510.1016/j.jaad.2016.10.042 28041632
   [Google Scholar]
9. KimballA.B. JemecG.B.E. AlaviA. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.Lancet20234011037874776110.1016/S0140‑6736(23)00022‑3 36746171
   [Google Scholar]
10. KimballA.B. JemecG.B.E. SayedC.J. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): Two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.Lancet2024403104432504251910.1016/S0140‑6736(24)00101‑6 38795716
    [Google Scholar]
11. GlattS. JemecG.B.E. FormanS. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa.JAMA Dermatol.2021157111279128810.1001/jamadermatol.2021.2905 34406364
    [Google Scholar]
12. ACELYRIN, INC. Announces top-line results from placebo-controlled clinical trial of izokibep for moderate-to-severe hidradenitis suppurativa.Available from: https://www.biospace.com/article/releases/acelyrin-inc-announces-top-line-results-from-placebo-controlled-clinical-trial-of-izokibep-for-moderate-to-severe-hidradenitis-suppurativa/ 2023
13. MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa.Available from https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-immunotherapeutics-achieves-landmark-milestone-positive 2023
14. Osorio-GómezG.F. Ortiz-ÁlvarezJ. Diaz-CecaD. Guijarro-SánchezC. Conejo-Mir SánchezJ. Fernández CrehuetP. Brodalumab for moderate–severe hidradenitis suppurativa: An open‐label multicentric cohort study in real clinical practice.Australas. J. Dermatol.202465325425910.1111/ajd.14267 38597096
    [Google Scholar]
15. GaoJ.L. OttoT.S. PorterM.L. KimballA.B. Hidradenitis suppurativa: New targets and emerging treatments.Am. J. Clin. Dermatol.202425576577810.1007/s40257‑024‑00880‑1 39060744
    [Google Scholar]